A Phase 2 Study of the Dual mTOR Inhibitor MLN0128 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC)
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Sapanisertib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 06 Mar 2018 Status changed from active, no longer recruiting to discontinued.
- 06 Mar 2018 Results published in the Investigational New Drugs
- 03 Oct 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.